Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you. Click here.

MATN: Positive Interim Results for ARTIVeda™; Will Approach FDA for EUA…


By David Bautz, PhD



Business Update

Positive Interim Data for ARTIVeda™ in COVID-19 Trial

On January 13, 2021, Mateon Therapeutics, Inc. (OTC:MATN) announced positive interim data for ARTIVeda™/ArtiShield™, the company’s lead Ayurvedic drug against COVID-19 (ARTIVeda in India and ArtiShield in the rest of the world).

The company is currently conducting the ARTI-19 global study of ARTIVeda in India with additional clinical sites set to open in Nigeria and Peru. The trial is on pace to have 120 subjected enrolled in India by the end of January 2021 and as of January 13, 2021 a total of 114 patents had been randomized. An interim analysis was performed for the first 60 patients, with all participants in the trial graded according to the WHO scale as shown in the following figure (WHO).

Patients are being treated with or without ARTIVeda along with standard of care (SOC), which is defined as treatment with remdesivir, ivermectin, dexamethasone, heparin, paracetamol, B complex, vitamin C, and zinc. Results from the interim analysis showed that:

• A majority of the 60 patients treated with ARTIVeda plus SOC recovered faster than SOC alone, with the median time to asymptomatic WHO scale of 1 being five days for ARTIVeda plus SOC compared to 14 days for SOC alone.

• Patients who had higher initial disease score showed greater response to ARTIVeda:

◦ WHO scale 2,3,4: P=0.0369, RR=1.476 (0.8957-2.433)

◦ WHO scale 3,4: P=0.026, RR=1.581 (0.9094-2.747)

◦ WHO scale 4: P=0.0043, RR=2.038 (0.9961-4.168)

The ARTI-19 trial is a Phase IV study to evaluate the safety and efficacy of ARTIVeda in patients suffering from COVID-19, with an emphasis on moderate patients (WHO scale 4-5). It is comparing SOC plus daily oral administration of Artemisia absinthium powder 500 mg for five days to SOC alone, with the option to repeat dosing until the disease is resolved or the subject is discharged up to three consecutive cycles.

Artemisinin is one of the active components of ArtiShield and is known to inhibit the TGF-β signaling pathway and neutralize SARS-CoV-2 in vitro at a concentration of 0.45 μg/mL while exhibiting a safety index of 140, which is better than remdesivir and chloroquine. In addition, a recent publication described a virtual screening of over 200,000 natural compounds from the ZINC library (Sterling et al., 2015) to identify leads with the highest binding affinity to the SARS-CoV-2 S protein, of which artemisinin was one of four selected (Alazmi et al., 2020). Lastly, a study published in Nov. 2020 showed that the combination of artemisinin and piperaquine had a therapeutic effect on COVID-19 by decreasing the mean time to reach undetectable viral RNA (Li et al., 2020). The aforementioned data suggest that artemisinin is active during all phases of COVID-19: inhibiting viral replication following exposure, alleviating symptoms during peak viral infection, and preventing lung damage during recovery.


We’re glad to see that the ARTI-19 trial continues to produce promising results in line with what we expected and with final data likely to be available in the second quarter of 2021 the company will be approaching regulatory agencies for potential EUA such that ARTIVeda can be sold as a treatment for COVID-19 as quickly as possible. We look forward to the final results from the trial, as ARTIVeda appears like it may offer a cost-effective COVID-19 treatment. With no changes to our model our valuation remains at $0.70.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

User ID:
Remember my ID: